mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company

Daily Archives: 01.08.2014

Home > News > Daily Archives: 01.08.2014

Eleventa has enrolled first patients in Phase III multicenter clinical trial

01.08.2014 by in category News

Eleventa has enrolled first patients in Phase III multicenter clinical trial Russian biotech company Eleventa is enrolling its first patients at 20 Russian clinical centers in its Phase III clinical trial for the anti-inflammatory drug OC000459.  The drug is aimed at the treatment of mild to moderate bronchial asthma.  Eleventa is supported by investments from […]

0 0 Read more

 

© Eleventa, 2012—2020